Sagent Pharmaceuticals Inc. (SGNT) announced the launch of Acetazolamide for Injection, USP, the generic form of the carbonic anhydrase inhibitor Diamox, in a latex-free vial presentation.
According to IMS data for the 12 months ending September 2012, the US market for Acetazolamide for Injection, USP approximated $9.5 million.
Acetazolamide for Injection, USP is indicated for adjunctive treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); and chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.